store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Deferoxamine [70-51-9]
Référence T124358-1mg
Conditionnement : 1mg
Marque : TargetMol
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Deferoxamine
Catalog No. T124358 CAS 70-51-9
Synonyms: Deferoxamine B, Desferrioxamine B
Deferoxamine（Desferrioxamine B） is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may improve neurological dysfunction by inhibiting iron death and neuroinflammation following traumatic brain injury.Desferrioxamin-B has antioxidant, antiproliferative, Deferoxamine has antioxidant, antiproliferative, and antitumor activities, and can induce HIF-1α production, apoptosis and autophagy in cancer cells.Desferrioxamin-B can be used in the treatment of acute iron toxicity and COVID-19 related diseases.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Deferoxamine, CAS 70-51-9
| Description | Deferoxamine（Desferrioxamine B） is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may improve neurological dysfunction by inhibiting iron death and neuroinflammation following traumatic brain injury.Desferrioxamin-B has antioxidant, antiproliferative, Deferoxamine has antioxidant, antiproliferative, and antitumor activities, and can induce HIF-1α production, apoptosis and autophagy in cancer cells.Desferrioxamin-B can be used in the treatment of acute iron toxicity and COVID-19 related diseases. |
| In vitro | Deferoxamine (1 mM; 16 hours or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and reduces ROS in MEF cells.[1] Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and induces increased p-Akt/total Akt/PKB levels.[2] Deferoxamine (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.[3]. Deferoxamine (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis in mesenchymal stem cells.[3] Deferoxamine (10 μM; 3 days) affects the expression of mesenchymal stem cell adhesion proteins[3] Deferoxamine (100 μM; 24 h) induces autophagy-mediated by HIF-1α levels in SH-SY5Y cells.[4] |
| In vivo | Deferoxamine (6.57 μg/mouse; drip; once daily for 21 days) promotes wound healing and increases neovascularization in aged or diabetic mice.[1] Deferoxamine (200 mg/kg; i.p.; once daily for 2 weeks) causes HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo.[2] |
| Synonyms | Deferoxamine B, Desferrioxamine B |
| Molecular Weight | 560.68 |
| Formula | C25H48N6O8 |
| CAS No. | 70-51-9 |
Storage
Solubility Information
DMSO: 10 mg/mL (17.84 mM), Sonication is recommended.
H2O: 7.14mg/ml(12.74mM)
References and Literature
1. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e. 2. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47. 3. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. 4. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205.